©2024 Stanford Medicine
Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy
Recruiting
I'm InterestedTrial ID: NCT00349830
Purpose
The purpose of this study is to measure the levels of serum proteins and other biomarkers in
cancer patients and in patients suspected of having cancer. We believe that some of these
markers may be useful for confirming the diagnosis or for selecting patients for specific
types of cancer therapies. These markers may also help to predict response to therapy,
relapse after therapy, and survival after therapy.
Official Title
Development of Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy
Stanford Investigator(s)
Maximilian Diehn, MD, PhD
Jack, Lulu, and Sam Willson Professor and Professor of Radiation Oncology (Radiation Therapy)
Quynh-Thu Le, MD
Katharine Dexter McCormick and Stanley McCormick Memorial Professor and Professor, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS)
Elizabeth Kidd
Associate Professor of Radiation Oncology (Radiation Therapy)
Billy W Loo, Jr, MD PhD FASTRO FACR
Professor of Radiation Oncology (Radiation Therapy)
Eligibility
1. Age > or = 18; for the samples collected under the NIH grant, no subjects below the
age of 20 will be enrolled.
2. Prior diagnosis of cancer or suspected of having cancer
3. Karnofsky performance status of greater than 70
4. Standard pretreatment evaluation
5. Signed Stanford University Human Subjects Committee consent
Intervention(s):
procedure: blood draw
Recruiting
I'm InterestedContact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Rene Bonilla
650-498-7703